• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 3, 2017

View Archived Issues

Other news to note

Biomarin Pharmaceutical Inc., of San Rafael, Calif., said the EMA granted access to its Priority Medicines (PRIME) regulatory initiative for the company's investigational gene therapy treatment for severe hemophilia A, BMN 270. Read More

Financings

Hemispherx Biopharma Inc., of Philadelphia, said it entered definitive agreements with several institutional investors for an offering of shares of common stock with gross proceeds of about $1 million in a registered direct offering. Read More

Earnings

Merck & Co. Inc., of Kenilworth, N.J., fell 1 percent short of expectations in the fourth quarter of 2016, mainly blamed on lower sales of Januvia/Janumet (sitagliptin), Zetia (ezetimibe), Zostavax (zoster vaccine live) and Cubicin (daptomycin), though sales of PD-1 inhibitor Keytruda (pembrolizumab), at $483 million, marginally beat the consensus guess of $470 million. Read More

Regulatory front

President Donald Trump's two-for-one regulation memo is now an executive order. Slated for publication in Friday's Federal Register, the order instructs federal agencies to identify at least two regulations to be withdrawn for every new regulation issued. Read More

Clotting, hypertension, inflammation linked

Factor XI, a coagulation factor that is part of the intrinsic blood clotting pathway, is part of a newly discovered circuit that links coagulation, inflammation and hypertension. Researchers described the circuit, which breaks ground scientifically as well as offering potential therapeutic strategies to treat often-co-morbid diseases, in the Feb. 1, 2017, issue of Science Translational Medicine. Read More

Mustang Bio saddles up with $94.5M private placement

Fortress Biotech Inc. subsidiary Mustang Bio Inc. closed on a $94.5 million private placement financing. It plans to use the funds to advance its two lead chimeric antigen receptor T-cell (CAR T) immunotherapies, MB-101 and MB-102, through phase I data readouts early next year and to grow its pipeline by exploring additional applications for its CAR T technology beyond its initial focus in brain cancer and acute myeloid leukemia. Read More

Aviragen stumbles on phase IIa efficacy in RSV but strong safety the bigger goal

Shares (NASDAQ:AVIR) of Aviragen Therapeutics Inc. took a drubbing after the company reported following Wednesday's market close that its double-blind, placebo-controlled phase IIa study of BTA585 in adults challenged intranasally with respiratory syncytial virus (RSV) missed the primary endpoint of reducing viral load. Read More

Arix planning London IPO, seeks $125M to invest in 'best science'

LONDON – Arix Bioscience Ltd. is to float on the main market of the London Stock Exchange, raising up to £100 million (US$125.6 million) to form and fund drug discovery and development companies from startup to maturity. Read More

Treated as Royalty: $100M positions Cytokinetics well re Amgen with omecamtiv

Cytokinetics Inc. kept mum on the eventual sales force for omecamtiv mecarbil, possible changes in the Royalty Pharma deal's assigned percentage, and an additional safety trial with the phase III candidate, as well as potential reimbursement from Amgen Inc. for "certain activities" in co-promoting. Read More

In the clinic

Amag Pharmaceuticals Inc., of Waltham, reported results from its pharmacokinetic study designed to demonstrate comparable bioavailability of the subcutaneous auto-injector product and the current intramuscular (IM) injection form of Makena (hydroxyprogesterone caproate injection) in about 120 healthy postmenopausal women. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe